Improving Selective Androgen Receptor Modulator Discovery and Preclinical Evaluation

The document from 2009 addresses the challenges in developing selective androgen receptor modulators (SARMs) and the need for better preclinical evaluation methods. It emphasizes the importance of understanding AR selectivity at the molecular level to create safer and more effective treatments for conditions like androgenic alopecia, prostate cancer, and muscle wasting. The paper suggests that current evaluation methods, such as the Hershberger assay, may not accurately predict safety and efficacy, and advocates for the use of quantitative gene transcription as a more accurate endpoint. It also proposes the development of an AR selectivity transcription profile and the use of cell-based assays with tissue-selective AR-responsive promoters for SARM discovery. The document concludes that a more comprehensive preclinical model should include all AR-responsive tissues and measure AR activity in both male and female animals to better predict human outcomes.